| Home | E-Submission | Sitemap | Contact Us |  
Cancer Research and Treatment > Volume 43(1); 2011 > Article
Park, Yang, Kim, Jang, Jang, Lee, Jin, Pham, Thi, Lim, Lee, Hong, Yoon, and Lee: Alpha-Type 1 Polarized Dendritic Cells Loaded with Apoptotic Allogeneic Breast Cancer Cells Can Induce Potent Cytotoxic T Lymphocytes against Breast Cancer



Various tumor antigens can be loaded onto dendritic cells (DCs) to induce a potent cytotoxic T lymphocyte (CTL) response in DC-based immunotherapy against breast cancer. However, in the clinical setting, obtaining a sufficient number of autologous tumor cells as a source of tumor antigens is a laborious process. We therefore investigated the feasibility of immunotherapy using breast-cancer-specific CTLs generated in vitro by use of alpha-type 1 polarized DCs (α DC1s) loaded with ultraviolet B-irradiated cells of the breast cancer cell line MCF-7.

Materials and Methods

αDC1s were induced by loading allogeneic tumor antigen generated from the MCF-7 UVB-irradiated breast cancer cell line. Antigen-pulsed αDC1s were evaluated by morphological and functional assays, and the breast-cancer-specific CTL response was analyzed by cytotoxic assay.


The αDC1s significantly increased the expression of several molecules related to DC maturation without differences according to whether the αDC1s were loaded with tumor antigens. The αDC1s showed a high production of interleukin-12 both during maturation and after subsequent stimulation with CD40L, which was not significantly affected by loading with tumor antigens. Breast-cancer-specific CTLs against autologous breast cancer cells were successfully induced by αDC1s loaded with apoptotic MCF-7 cells.


Autologous DCs loaded with an allogeneic breast cancer cell line can generate potent breast-cancer-specific CTL responses. This may be a practical method for cellular immunotherapy in patients with breast cancer.


Breast cancer is one of the most common malignancies in women and is the second leading cause of cancer death [1]. In the modern era of breast cancer treatment, rapid progress has led to a broad spectrum of therapeutic strategies for improving clinical outcomes. In addition to improvements in therapeutic modalities including chemotherapy, radiation, hormone manipulation and surgery, immunotherapy has emerged as an effective adjunct for the treatment of breast cancer [2,3]. The possible use of immunotherapy in breast cancer treatment was suggested by several findings. One such finding was the detection of a protective effect of human leukocyte antigen (HLA) class II alleles in breast cancer [4,5]. Another finding was that T cells recognizing mucin (MUC)-1 and HER2/neu-derived antigens could be isolated from the peripheral blood of breast cancer patients [5,6]. Furthermore, graft-versus-tumor effects were shown to be induced by donor lymphocyte infusion in patients who relapsed after allogeneic stem cell transplantation [7].
Dendritic cells (DCs) are the major antigen-presenting cells of the immune system. Because of their ability to stimulate T cells, DCs act as a link in antitumor immune responses between innate immunity and adaptive immunity [8]. Once activated by inflammatory stimuli or infectious agents, immature DCs undergo maturation, which results in the expression of high levels of major histocompatibility complex (MHC) and co-stimulatory molecules which present antigens to activate T cells [9]. DC-based vaccines are the most attractive tool for cancer immunotherapy and have been used in more than 20 malignancies; most commonly melanoma, prostate cancer, colorectal carcinoma and multiple myeloma. In an attempt to increase the potency of DCs, alpha-type 1 polarized DCs (αDC1s) were developed through the use of cytokine combinations. The αDC1s are induced to mature by addition of an αDC1-polarizing cytokine cocktail containing interleukin (IL)-1β, tumor necrosis factor (TNF)-α, interferon (IFN)-α, IFN-γ and polyinosinic : polycytidylic acid [poly(I : C)]). Compared with standard DCs, αDC1s generate strong, functional cytotoxic T lymphocytes (CTLs) in several diseases [10,11].
The ideal DC-based vaccination in breast cancer would induce tumor-specific immunity to breast cancer without causing clinically significant autoimmunity. One approach to enhancing the specificity of vaccines is to target them against specific protein antigens that are over-expressed on breast cancer cells. These tumor antigens, such as MUC-1, HER2/neu and telomerase, are also expressed on tumor cells of other epithelial-derived cancers and are loaded onto DCs as a source of tumor antigen which will not target multiple tumor variants [12-14]. The use of whole tumor cells instead of a single protein antigen for tumor antigen in DCs, may help to enhance breast cancer-specific cytolytic effects with unfractionated tumor-derived antigens. However, it is not only impractical to obtain sufficient amounts of purified autologous tumor cells for tumor antigens from breast cancer patients, but it is also unsuitable for those with a lower tumor-burden status. Therefore, to overcome this limitation, allogeneic tumor cells or established cancer cell lines from various tumors have been used as an alternative source of tumor-relevant antigens [15-17].
In the present study, we investigated the possibility of immunotherapy using autologous αDC1s loaded with ultraviolet B (UVB)-irradiated cells from the allogeneic breast cancer cell line MCF-7. We studied whether these cells could generate breast-cancer-specific CTLs against autologous cancer cells in patients with breast cancer.

Materials and Methods

1. Generation of αDC1s

The schema for the generation of DCs is shown in Fig. 1. Peripheral blood was collected from HLA-A0201-positive (HLA-A0201+) breast cancer patients after obtaining informed consent according to the protocol approved by the Chonnam National University Hwasun Hospital Institutional Review Board. Monocytes were isolated from peripheral blood by a two-step procedure as previously reported [18]. Briefly, mononuclear cells were isolated from the peripheral blood by density gradient centrifugation with Ficoll-Hypaque (Lymphoprep, Nycomed, Norway). The monocyte and lymphocyte fractions were isolated on density gradients with Percoll (Sigma-Aldrich, St. Louis, MO). The monocyte fraction was resuspended in AIM-V medium (Gibco-BRL, Grand Island, NY) at a density of 5×105 cells/500 µL and was allowed to adhere to 24-well plates for 45 minutes at 37℃ in 5% CO2.
After removal of nonadherent cells by gentle washing, immature DCs were generated by culturing the adhered monocytes in IMDM (Gibco-BRL) supplemented with 10% heat-inactivated fetal bovine serum (Hyclone, Logan, UT) and 1% penicillin-streptomycin (Gibco-BRL) for 6 days in 24-well plates at a density of 5×105 cells per well, in the presence of 50 ng/mL granulocyte-macrophage colony-stimulating factor (LG Biochemical, Daejeon, Korea) and 20 ng/mL IL-4 (R&D Systems, Minneapolis, MN). On day 6, the immature DCs were maturated with an αDC1-polarizing cocktail composed of IL-1β(25 ng/mL), TNF-α(50 ng/mL), IFN-α(3,000 units/mL, Intron-A-IFN-α-2b, Schering-Plough, Kenilworth, NJ), IFN-γ(1,000 units/mL, Strathmann Biotech, Hamburg, Germany) and poly(I : C) (20 µg/mL, Sigma-Aldrich). The mature αDC1s were then loaded with the UVB-irradiated tumor cells (HLA-A0201+) at a ratio of 2 : 1 at 2 hours after the addition of the maturating cytokines. The αDC1s loaded with apoptotic tumor cells were harvested on day 8.

2. Preparation of the UVB-irradiated tumor cells as an antigen source

To load tumor cells onto DCs, MCF-7 breast cancer cells (HLA-A0201+, adenocarcinoma, estrogen receptor positive) were irradiated with UVB (120 mJ/cm2) followed by overnight culture in RPMI-1640 (Gibco-BRL) without fetal bovine serum to induce apoptosis and were then thoroughly washed. The irradiated tumor cells were then loaded onto DCs 2 hours after the addition of maturating cytokines. The irradiated apoptotic cells were immediately confirmed by using annexin-V and propidium iodide (data not shown).

3. Preparation of breast cancer cells

Tumor tissues obtained from breast cancer patients by surgical resection were minced and lysed for 2-4 hours at 37℃ in AIM-V medium containing 0.4% collagenase type III. The mononuclear cells were separated by density gradient centrifugation with Ficoll-Hypaque (Lymphoprep) and cryopreserved until use as target cells in the cytotoxic assay.

4. Phenotypic expression of αDC1s and tumor-antigen uptake

Flow cytometry was performed using a FACSAria cell sorter (Beckon Dickinson, San Jose, CA) after labeling of cells with CD83-fluorescein isothiocyanate (FITC), CD86-FITC, and CCR7-FITC (PharMingen, San Diego, CA) and the relevant isotype controls (mouse IgG1 and IgG2a, PharMingen). Cell debris was eliminated from the analysis by forward- and side-scatter gating, and the data were analyzed with FACSDiva™ (Becton Dickinson, Heidelberg, Germany) and Win MDI ver. 2.9 (Bio-Soft Net).
To measure tumor-antigen uptake by αDC1s, MCF-7 cells were labeled with PKH67-GL-FITC (Sigma-Aldrich) before UVB-irradiation. After loading of tumor antigen onto DCs at a ratio of 1 : 2 on day 6, the αDC1s loaded with the apoptotic MCF-7 cells were stained with CD11c-phycoerythrin (PE) after harvesting on day 8 and were then analyzed by flow cytometry for tumor cell uptake (CD11c+/PKH67+). To morphologically confirm the tumor uptake of αDC1s, MCF-7 cells were labeled with PKH67-GL-Green and DCs were labeled with PKH26-GL-Red. The morphology of the cells' nuclei was observed by using a confocal microscope (Olympus, Center Valley, PA) at an excitation wave length of 350 nm for 4', 6-diamidino-2-phenylindole (DAPI) staining.

5. Cytokine analyses by enzyme-linked immunosorbent assay (ELISA)

The levels of IL-12p40, IL-12p70, IL-10 and IL-6 in the primary culture supernatants of the αDC1s were measured using Quantikine Immunoassay Kits (R&D Systems). Additionally, αDC1s harvested on day 8 were plated in 96-well plates at a density of 2×104 cells/well and were stimulated with CD40L-transfected J558 cells (as an analogue of CD40L-expressing Th cells; a kind gift of Dr. P. Lane, University of Birmingham, UK) at a density of 5×104 cells/well. After 24 hours, the supernatant was harvested, and the production of IL-12p70 was measured using ELISA kits (R&D Systems).

6. Allogeneic T cell stimulatory capacities

To examine the capacity of the DCs to stimulate the alloreactive T cells, allogeneic CD3+ T cells were obtained from peripheral blood mononuclear cells (PBMCs) from healthy donors by positive selection, using the magnetic activated cell sorter (MACS) system (Miltenyi Biotec, Auburn, CA). T cells (1×106 cells) were labeled with 10 µM carboxyfluorescein diacetate succinimidyl ester (CFSE; Molecular Probes™, Invitrogen, Paisley, UK) for 10 minutes at 37℃. After 2 washes, the CFSE-labeled T cells (2×104) were co-cultured with graded doses of irradiated (30 Gy) DCs. On day 5, the cultured cells were harvested and acquired on a FACSAria cell sorter (Becton Dickinson), and the data were analyzed with WinMDI ver. 2.9 software (Bio-Soft Net) to detect the dilution of CFSE dye. The results are expressed as the percentage of proliferated cells.

7. In vitro priming of CD4+CD45RA+ naïve T cells with DCs

Naïve CD4+ T cells were obtained from PBMCs of healthy volunteers by a negative selection process using a naïve CD4+ T isolation kit (MACS, Miltenyi Biotec). Purity of the isolated CD45RA+ cells was>95%, as determined by FACS assay with CD4-FITC and CD45RA-PE staining. CD4+CD45RA+ naïve T cells (2×104) were stimulated with 2×104 matured DCs that had been pre-incubated with 1 ng/mL of Staphylococcus aureus enterotoxin B in 96-well flat-bottomed plates. On day 5, 10 U/mL rIL-2 (R&D Systems) was added to each well. After 5 days, the cells were stimulated for 1 day with Dynabeads CD3/CD28 T Cell Expander (Invitrogen Dynal AS, Oslo, Norway). Supernatants from the re-stimulated cultures were assayed for Th1 cytokine, IFN-γ, and the Th2 cytokine, IL-4, using the BD OptEIA ELISA Set (BD Bioscience, San Diego, CA).
The production of Th1- and Th2-type cytokines at the single-cell level was measured by FACS analysis, using an intracellular cytokine staining protocol, as described previously [19]. Briefly, harvested T cells were stimulated with phorbol myristate acetate and ionomycin for 5 hours, and Brefeldin A (eBiosciences, San Diego, CA) was added during the last 2 hours of incubation. Cells were collected, fixed, permeabilized with a commercial IntraPrep Permeabilization Reagent (Beckman Coulter, Marseille, France) and were stained with FITC-labeled IFN-γ and PE-labeled IL-4 mAbs. The samples were acquired on a FACSAria cell sorter (Becton Dickinson) and were analyzed using WinMDI ver. 2.9 (Bio-Soft Net).

8. Induction of breast-cancer-specific CTLs

Autologous CD3+ T cells (purity>90%) were positively isolated using MACS (Miltenyi Biotec) from the lymphocyte fraction after Percoll isolation. T cells (1×106 cells) were sensitized by autologous αDC1s (1×105 cells) primed with apoptotic MCF7 cells. On day 3, rhuIL-2 (25 ng/mL, R&D Systems) and IL-7 (10 ng/mL, R&D Systems) were added. On day 10, the CTL lines were restimulated with the same DCs. On day 20, the number of antigen-specific T cells was analyzed by IFN-γ enzyme-linked immunospot (ELISPOT) assay. Autologous MCF-7 cells (HLA-A0201+ breast cancer cells), T-47D (HLA-A0201- breast cancer cells), PC-3 (prostate cancer cells) and K562 cells (chronic myeloid leukemia cells with natural killer [NK] cell activity) were used as target cells. To distinguish MHC-restricted cytotoxicity in CTL lines, IFN-γ-secreting cells were measured in the presence or absence of the mAbs W6/32 (MHC I antigen, 10 µg/mL). Additionally, autologous breast cancer cells obtained from patients were used as target cells with or without anti-MHC I antibody. The ELISOPT data were expressed as the mean number of spots (±standard deviation) per 0.5-2×105 T cells.


1. Characteristics of mature and polarized DCs in patients with breast cancer

After induction of the immature DCs, αDC1s were generated by addition of the αDC1 cytokine cocktail. The αDC1s showed typical morphology with large and branching structures that were aggregated among the cells. Phenotypic analysis showed that expressions of maturation marker (CD83), co-stimulatory molecule (CD86) and the predictive marker of migratory ability (CCR7) were significantly higher in αDC1s than in immature DCs. However, there were no differences in phenotypic expression between the αDC1s and the αDC1s loaded with apoptotic MCF-7 cells (Fig. 2).
To measure tumor antigen uptake by DCs, DCs loaded with apoptotic tumor cells were stained with CD11c. As shown in Fig. 3A, αDC1s very efficiently incorporated the tumor antigen (median, 22.3±8.5%; n=4) as measured by flow cytometry (CD11c+/PKH-67+). By use of a confocal microscope, apoptotic MCF-7 cells (PKH-67) were morphologically identified in the αDC1s (PKH-26) (Fig. 3B).

2. High level of IL-12p70 production by αDC1s in breast cancer

One of best ways of determining DC function is to examine cytokine secretion. IL-12p70 is an important cytokine for stimulating naïve T cells for Th1 polarization to benefit cancer treatment, but IL-10 is the main inhibitory cytokine for cancer treatment. As shown in Fig. 4, the αDC1s showed high IL-12p70 production during maturation. Furthermore, the αDC1s showed further production of IL-12p70 after subsequent stimulation with CD40L-transfected J558 cells (Fig. 4). This cytokine capacity of αDC1s was not significantly suppressed by loading the cells with tumor antigen. By contrast, production of the inhibitory cytokine IL-10 by αDC1s was not significant. IL-6 production was significantly higher by the αDC1s than by the immature DCs, which is consistent with the finding of a previous report [20], suggesting Th17 polarization of αDC1s.

3. αDC1s in patients with breast cancer promoted Th1 polarization of naïve T cells

To confirm whether the αDC1s could induce the differentiation of naïve T cells toward Th1, the naïve T cells were stimulated by the DCs. The αDC1s induced naïve T cells to not only increase the level of IFN-γ secretion but also decrease the level of IL-4 secretion (Fig. 5A). This finding suggests that αDC1s strongly promote Th1 polarization of naïve T cells in patients with breast cancer. This Th1 response was confirmed by flow cytometry to analyze the production of Th1-type and Th2-type cytokines at the single-cell level. The αDC1s could induce Th1 polarization (IFN-γ producing cells: 46.9%) compared with immature DCs (30.3%) (Fig. 5B).

4. αDC1s in patients with breast cancer showed strong allogeneic T cell stimulatory capacities

To evaluate the ability of DCs to stimulate T cell proliferation, allogeneic CD3+ T cells obtained from healthy donors were stimulated with DCs and an allogeneic mixed lymphocyte reaction assay was performed using the CFSE-based proliferation assay. As shown in Fig. 6, the percentage of proliferated T cells was significantly higher after stimulation of αDC1s than after stimulation of immature DCs and was dependent on the DC to T cell ratio. Loading of apoptotic tumor cells onto αDC1s did not significantly affect T cell proliferation.

5. Strong breast-cancer-specific CTLs were induced by potent DCs loaded with apoptotic allogeneic breast cancer cells

We next determined the tumor-specific generation of CTLs by DCs. The secretion of IFN-γ by the CTLs was measured in three independent experiments using the ELISPOT assay. Primed CD3+ T cells generated by the αDC1s loaded with apoptotic MCF-7 breast cancer cells, showed a larger number of IFN-γ-producing cells against MCF-7 breast cancer cells (Fig. 7A) and against autologous breast cancer cells obtained from breast tumor tissue (Fig. 7C), but not against irrelevant target cells such as T-47D (HLA-A0201- breast cancer cells) and PC-3 (prostate cancer cells). The specificity of the CTL response was confirmed by inhibition of IFN-γ-release with MHC class I-blocking mAb, indicating HLA class I-restricted action. When we used αDC1s without loading of apoptotic breast cancer cells as a control, the CTLs generated showed a fewer number of IFN-γ-producing cells against MCF-7 breast cancer cells (Fig. 7B). To evaluate the specificity of the cytotoxic response by CTLs, K562 cells, which are NK cell-sensitive chronic myeloid leukemia cells, were used as the target cells. Fewer IFN-γ-secreting cells were found against K562, which suggests a CTL-mediated, rather than an NK cell-mediated breast cancer response.


The development of breast cancer immunotherapies using molecular typing or genomic identification of breast cancer antigen has confirmed that specific biological types of breast cancer exist with different levels and patterns of antigen expression [21,22]. The identification of multiple antigenic targets in breast cancer should enable a potent antigen-specific immune response. In this report we have suggested an alternative approach to immunotherapy in which allogeneic cancer cells are used as a tumor-specific antigen for loading onto DCs. We successfully generated αDC1s from breast cancer patients, and the cells showed a high expression level for molecules related to DC maturation, significant production of IL-12p70, and potent generation of breast-cancer-specific CTLs. Additionally, the αDC1s demonstrated strong IL-12p70 production after CD40L stimulation and had a potent capacity to induce Th1 polarization on the basis of their high production of IFN-γ. The CTLs generated by the αDC1s demonstrated breast-cancer-specific killing effects in an MHC class I-restricted manner.
In clinical practice, allogeneic breast cancer cells prepared from MCF-7 cells might be an effective source of universal tumor antigen that could be used for loading onto αDC1s for the generation of breast-cancer-specific CTLs. This approach is similar to recent studies in other diseases showing that fusion cells generated by autologous DCs and allogeneic tumor cell lines could generate antigen-specific CTL responses [23,24]. The use of allogeneic cancer cells can avoid the necessary process of original tumor cell collection and simplify the culture of tumor cells [23,25]. Vaccination with autologous DCs primed with allogeneic tumor cell lines has potential applicability to the field of antitumor immunotherapy. These universal cell lines would provide several advantages for clinical applications, such as no limiting factor affecting tumor cell preparation and well-characterized features as a source of tumor-associated antigens.
We demonstrated that autologous αDC1s loaded with apoptotic MCF-7 cells could prime T cells to generate the tumor-specific CTLs, which can kill breast cancer cells. More importantly, the pulsed αDC1s from the HLA-A0201+ patients could induce CTL activity against autologous breast cancer cells, and the pulsed αDC1s from HLA0201- patients generated a breast-cancer-specific CTL response with less potency than the response generated from HLA0201+ cells. The autologous αDC1s pulsed with apoptotic MCF-7 cells from HLA-A0201+ patients could stimulate alloreactive T cells due to the presence of allogeneic HLA class I molecules from an allogeneic breast cancer cell line. Moreover, alloreactive T cells could secrete cytokines, which may contribute to enhancement or maintenance of the tumor-specific CTL response. The inhibition of MHC class molecules by use of anti-MHC class antibody prevented the development of CTL responses specific for autologous breast cancer cells from HLA-A0201+ patients. Thus, the use of an allogeneic tumor cell line as a source of tumor antigens could generate MHC class-restricted T cell responses against autologous breast cancer cells. A major drawback of this approach is the need to perform HLA typing of patients and allogeneic tumor cell lines.


In this study, autologous αDC1s loaded with allogeneic breast cancer cells could generate strong breast-cancer-specific CTLs against autologous breast cancer cells. This may offer a highly feasible and effective method for cell-based immunotherapy in patients with breast cancer.


This study was financially supported by grant no. RTI05-01-01 from the Regional Technology Innovation Program of the Ministry of Commerce, Industry and Energy, Republic of Korea.

Conflicts of Interest

Conflict of interest relevant to this article was not reported.


1. Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist. 2003;8:541–552. PMID: 14657533
crossref pmid
2. Anderson KS. Tumor vaccines for breast cancer. Cancer Invest. 2009;27:361–368. PMID: 19358018
crossref pmid pmc
3. Curigliano G, Spitaleri G, Dettori M, Locatelli M, Scarano E, Goldhirsch A. Vaccine immunotherapy in breast cancer treatment: promising, but still early. Expert Rev Anticancer Ther. 2007;7:1225–1241. PMID: 17892423
crossref pmid
4. Chaudhuri S, Cariappa A, Tang M, Bell D, Haber DA, Isselbacher KJ, et al. Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles. Proc Natl Acad Sci U S A. 2000;97:11451–11454. PMID: 11027344
crossref pmid pmc
5. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 1994;54:16–20. PMID: 7505195
6. Jerome KR, Domenech N, Finn OJ. Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J Immunol. 1993;151:1654–1662. PMID: 8393050
7. Carella AM, Beltrami G, Corsetti MT, Nati S, Musto P, Scalzulli P, et al. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet. 2005;366:318–320. PMID: 16039336
crossref pmid
8. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–252. PMID: 9521319
crossref pmid
9. Reid DC. Dendritic cells and immunotherapy for malignant disease. Br J Haematol. 2001;112:874–887. PMID: 11298582
crossref pmid
10. Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, et al. Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 2004;64:5934–5937. PMID: 15342370
crossref pmid
11. Lee JJ, Foon KA, Mailliard RB, Muthuswamy R, Kalinski P. Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia. J Leukoc Biol. 2008;84:319–325. PMID: 18426971
crossref pmid pmc
12. Gilewski T, Adluri S, Ragupathi G, Zhang S, Yao TJ, Panageas K, et al. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res. 2000;6:1693–1701. PMID: 10815887
13. Murray JL, Gillogly ME, Przepiorka D, Brewer H, Ibrahim NK, Booser DJ, et al. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res. 2002;8:3407–3418. PMID: 12429628
14. Parkhurst MR, Riley JP, Igarashi T, Li Y, Robbins PF, Rosenberg SA. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res. 2004;10:4688–4698. PMID: 15269141
crossref pmid pmc
15. Raje N, Hideshima T, Davies FE, Chauhan D, Treon SP, Young G, et al. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol. 2004;125:343–352. PMID: 15086415
crossref pmid
16. Lee JJ, Choi BH, Kang HK, Park MS, Park JS, Kim SK, et al. Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates. Leuk Lymphoma. 2007;48:2022–2031. PMID: 17917970
crossref pmid
17. Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, et al. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother. 2006;29:545–557. PMID: 16971810
crossref pmid
18. Muthuswamy R, Urban J, Lee JJ, Reinhart TA, Bartlett D, Kalinski P. Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res. 2008;68:5972–5978. PMID: 18632653
crossref pmid pmc
19. Takei M, Tachikawa E, Hasegawa H, Lee JJ. Dendritic cells maturation promoted by M1 and M4, end products of steroidal ginseng saponins metabolized in digestive tracts, drive a potent Th1 polarization. Biochem Pharmacol. 2004;68:441–452. PMID: 15242811
crossref pmid
20. Trepiakas R, Pedersen AE, Met O, Hansen MH, Berntsen A, Svane IM. Comparison of alpha-type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients. Vaccine. 2008;26:2824–2832. PMID: 18450338
crossref pmid
21. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–752. PMID: 10963602
crossref pmid
22. Porter DA, Krop IE, Nasser S, Sgroi D, Kaelin CM, Marks JR, et al. A SAGE (serial analysis of gene expression) view of breast tumor progression. Cancer Res. 2001;61:5697–5702. PMID: 11479200
23. Matsumoto S, Saito H, Tsujitani S, Ikeguchi M. Allogeneic gastric cancer cell-dendritic cell hybrids induce tumor antigen (carcinoembryonic antigen) specific CD8+ T cells. Cancer Immunol Immunother. 2006;55:131–139. PMID: 15891883
crossref pmid
24. Delirezh N, Moazzeni SM, Shokri F, Shokrgozar MA, Atri M, Kokhaei P. Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro . Cell Immunol. 2009;257:23–31. PMID: 19306994
crossref pmid
25. Salcedo M, Bercovici N, Taylor R, Vereecken P, Massicard S, Duriau D, et al. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother. 2006;55:819–829. PMID: 16187085
crossref pmid
Fig. 1
Schema of the generation of dendritic cells (DCs) in patients with breast cancer in this study. PBMCs, peripheral blood mononuclear cells; D, day; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL, interleukin; TNF, tumor necrosis factor; IFN, interferon; poly-I : C, polyinosinic : polycytidylic acid; αDC1, alpha-type 1 polarized DCs; IMDM, Iscove's Modified Dulbecco's medium; FBS, fetal bovine serum; UVB, ultraviolet B.
Fig. 2
Phenotypic expression of dendritic cells (DCs). The expressions of several molecules (CD83, CD86 and CCR7) related to DC maturation were significantly higher in the alpha-type 1 polarized DCs (αDC1s) than in the immature DCs (iDCs). However, there were no differences in phenotypic expression between the αDC1s and the αDC1s loaded with apoptotic MCF-7 breast cancer cells. Data are from one representative experiment of four independent experiments.
Fig. 3
Efficacy of tumor antigen uptake by dendritic cells (DCs). DCs were loaded with PKH67-labeled UVB-irradiated MCF-7 breast cancer cells (a ratio of 2 : 1) 2 hr after the addition of maturation-inducing cytokines on day 6. Mature DCs were harvested on day 8 and identified by CD11c expression. (A) The tumor antigen uptake of the alpha-type 1 polarized DCs (αDC1s) was measured by the percent of double-positive cells using flow cytometry. (B) After labeling MCF-7 cells with PKH67-GL-Green and DCs with PKH26-GL-Red, cell morphology was observed by using a confocal microscope at an excitation wavelength of 350 nm for DAPI. Apoptotic MCF-7 cells (yellow) were confirmed in the αDC1s.
Fig. 4
Comparison of cytokine production by dendritic cells (DCs). Production of interleukin (IL)-12p40, IL-12p70, IL-10 and IL-6 during maturation of the alpha-type 1 polarized DCs (αDC1s) and the αDC1s loaded with apoptotic tumor cells and during re-stimulation with 40L-tranfected J558 cells for 24 hr after maturation. Results, expressed as mean (pg/mL)±standard deviation of triplicate cultures, are from one representative experiment of three. iDCs, immature DCs.
Fig. 5
Alpha-type 1 polarized DCs (αDC1s) induce naïve CD4+ T cells to secrete Th1 cytokines. Allogeneic naïve CD4+CD45RA+ T cells were primed with DCs for 5 days and then stimulated with rIL-2. On day 10, the cells were re-stimulated with Dynabeads CD3/CD28 T cell expander for 1 day. (A) Interleukin (IL)-4 and interferon (IFN)-γ levels measured in culture supernatants by enzyme-linked immunosorbent assay. (B) IL-4 and IFN-γ expression by intracellular staining at the single-cell level. The results are one representative experiment of three independent experiments and are expressed as the percent of cytokine-producing cells. iDCs, immature DCs.
Fig. 6
Comparison of allogeneic T cell stimulatory capacities of dendritic cells (DCs). In a carboxyfluorescein diacetate succinimidyl ester (CFSE)-based proliferation assay, CFSE-labeled allogeneic CD3+ T cells (20,000 cells/well) were stimulated for 5 days with graded doses of irradiated DCs. Flow cytometry was used to measure the percent of CFSE-proliferated cells. The stimulatory capacity of the alpha-type 1 polarized DCs (αDC1s) was significantly higher in a dose-dependent manner than that of the immature DCs (iDCs), and there was no effect on T cell proliferation by loading of apoptotic tumor cells onto αDC1s. Data are representative histograms of fluorescence-activated cell sorting analysis from one of three independent experiments.
Fig. 7
Ezyme-linked immunospot (ELISPOT) assay to measure the interferon (IFN)-γ release of breast-cancer-specific cytotoxic T lymphocytes (CTLs). Autologous CD3+ T cells were stimulated with dendritic cells (DCs) loaded with apoptotic MCF-7 cells two times every 10 days. On day 20, the CTLs were co-cultured with autologous target cells (MCF-7, HLA-A0201+) and irrelevant target cells (T-47D, HLA-A0201- breast cancer cells; PC3, prostate cancer cells; K562, natural killer cell-sensitive chronic myeloid leukemia cells). (A) Number of IFN-γ-secreting cells from CTLs stimulated with the MCF-7-loaded-alpha-type 1 polarized DCs (αDC1s) (A) and the MCF-7-unloaded-αDC1s (B). Anti-major histocompatibility complex (MHC) class I antibodies were used to confirm the MHC class I-restricted recognition of breast-cancer-specific CTLs. Breast cancer cells were isolated from tumor tissue of patients and the CTLs were co-cultured with the breast cancer cells as target cells (C). The ELISPOT data are the mean (±standard deviation) number of IFN-γ-producing cells of triplicate cultures in three independent experiments.
PDF Links  PDF Links
PubReader  PubReader
ePub Link  ePub Link
Full text via DOI  Full text via DOI
Download Citation  Download Citation
CrossRef TDM  CrossRef TDM
Related article
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association. All rights reserved.                 Developed in M2PI